Neurosense, FDA to meet on Phase 3 plans for PrimeC in ALS
Neurosense Therapeutics will meet with the U.S. Food and Drug Administration (FDA) Nov. 6 to discuss plans for a Phase…
Articles by Marisa Wexler, MS
Radicava ORS slows ALS disease progression, improves survival
Treatment with Radicava ORS (edaravone) significantly slowed declines in physical function and improved survival outcomes for people with…
Repurposed drugs fail to slow disease progression in ALS trial
Neither memantine nor trazodone, two medications approved to treat other conditions, was able to slow disease progression in people with…
Initiative to use AI technologies to improve communication in ALS
The Scott-Morgan Foundation (SMF), a nonprofit that’s pioneering assistive technology innovation, will lead a new initiative using artificial intelligence…
High levels of metals in body raise ALS risk, affect patient survival
People with higher levels of certain metals in their blood and urine are more likely to develop amyotrophic lateral…
Brain-computer interface allows man with ALS to communicate
A brain-computer interface allowed Casey Harrell, a 45-year-old man with amyotrophic lateral sclerosis (ALS) whose disease had made it…
Deficits in protein-metal complexes may underlie SOD1-ALS: Study
Changes in how the SOD1 protein associates with metal molecules seem to be key for how mutations affecting this protein…
PrimeC normalizes iron biomarkers in Phase 2b ALS trial
One year of treatment with the experimental oral therapy PrimeC led to improved iron accumulation in people with amyotrophic…
Clene submits new CNM-Au8 data to FDA ahead of upcoming meeting
Clene will soon meet with the U.S. Food and Drug Administration (FDA) to discuss the potential pathway to accelerated…
Mutation in IGFBP7 gene linked to rare phenomenon of ALS reversal
A mutation in the IGFBP7 gene is associated with a very rare phenomenon in which people with amyotrophic lateral…